


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Original) A compound of the formula I,



in which:

A1, A2, A3, A4, A5, A6, A7 and A8

independently of one another are chosen from nitrogen, CH and CR(5), at least one of these groups being nitrogen and at least 4 of these groups being CH;

R(1) is C(O)OR(9), SO₂R(10), COR(11), C(O)NR(12)R(13) or C(S)NR(12)R(13);
wherein R(9), R(10), R(11) and R(12)

independently of one another are C_xH_{2x}-R(14);

where x is 0, 1, 2, 3 or 4, and

x cannot be 0 if R(14) is OR(15) or SO₂Me;

R(14) is alkyl having 1, 2, 3, 4, 5 or 6 atoms, cycloalkyl having 3, 4, 5, 6, 7, 8, 9, 10 or 11 carbon atoms, CF₃, C₂F₅, C₃F₇, CH₂F,

CHF₂, OR(15), SO₂Me, substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted biphenyl, substituted or unsubstituted furyl, substituted or unsubstituted thienyl or a substituted or

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

unsubstituted N-containing heteroaromatic having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms,

where the substituted phenyl, substituted naphthyl, substituted biphenyl, substituted furyl, substituted thienyl and the substituted N-containing heteroaromatic are each independently substituted by 1, 2 or 3 substituents chosen from F, Cl, Br, I, CF₃, OCF₃, NO₂, CN, COOMe, CONH₂, COMe, NH₂, OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R(15) is alkyl having 1, 2, 3, 4 or 5 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, CF₃ substituted phenyl or unsubstituted phenyl, wherein the substituted phenyl is substituted by 1, 2 or 3 substituents chosen from F, Cl, Br, I, CF₃, NO₂, CN, COOMe, CONH₂, COMe, NH₂, OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino; and

R(13) is hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms or CF₃;

R(2) is hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms or CF₃;

R(3) is CyH_{2y}-R(16);

where y is 0, 1, 2, 3 or 4, and
y cannot be 0 if R(16) is OR(17) or SO₂Me;

R(16) is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7, 8, 9, 10 or 11 carbon atoms, CF₃, C₂F₅, C₃F₇, CH₂F, CHF₂,

OR(17), SO_2Me , substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted furyl, substituted or unsubstituted thienyl or a substituted or unsubstituted N-containing heteroaromatic having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms,

where the substituted phenyl, substituted naphthyl, substituted furyl, substituted thienyl and the substituted N-containing heteroaromatic are each independently substituted by 1, 2 or 3 substituents chosen from F, Cl, Br, I, CF_3 , OCF_3 , NO_2 , CN, COOMe , CONH_2 , COMe , NH_2 , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino; and

R(17) is hydrogen, alkyl having 1, 2, 3, 4 or 5 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, CF_3 , substituted phenyl, unsubstituted phenyl, substituted 2-, 3- or 4-pyridyl, or unsubstituted 2-, 3- or 4-pyridyl,

where the substituted phenyl and substituted 2-, 3- or 4-pyridyl are each independently substituted by 1, 2 or 3 substituents chosen from F, Cl, Br, I, CF_3 , OCF_3 , NO_2 , CN, COOMe , CONH_2 , COMe , NH_2 , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

or

R(3) is $\text{CHR}(18)\text{R}(19)$;

where R(18) is hydrogen or $\text{C}_z\text{H}_{2z}\text{-R}(16)$, where R(16) is defined as indicated above;

z is 0, 1, 2 or 3;

R(19) is COOH , CONH_2 , $\text{CONR}(20)\text{R}(21)$, $\text{COOR}(22)$ or CH_2OH ;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

R(20) is hydrogen, alkyl having 1, 2, 3, 4 or 5 carbon atoms, C_vH_{2v} -
 CF_3 , substituted C_wH_{2w} - phenyl or unsubstituted C_wH_{2w} -
phenyl,
where the phenyl ring of the substituted C_wH_{2w} - phenyl
is substituted by 1, 2 or 3 substituents chosen from F,
Cl, Br, I, CF_3 , NO_2 , CN, COOMe, $CONH_2$, COMe,
 NH_2 , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy
having 1, 2, 3 or 4 carbon atoms, dimethylamino,
sulfamoyl, methylsulfonyl and methylsulfonylarnino;
v is 0, 1, 2 or 3;
w is 0, 1, 2 or 3;

R(21) is hydrogen or alkyl having 1, 2, 3, 4 or 5 carbon atoms; and
R(22) is alkyl having 1, 2, 3, 4 or 5 carbon atoms;

R(4) is hydrogen, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms or CF_3 ;

or

R(3) and R(4)

together are a chain of 4 or 5 methylene groups, of which one methylene group
can be replaced by -O-, -S-, -NH-, -N(methyl)- or -N(benzyl)-;

R(5) is independently of one another chosen from F, Cl, Br, I, CF_3 , NO_2 , CN,
COOMe, $CONH_2$, COMe, NH_2 , OH, alkyl having 1, 2, 3 or 4 carbon atoms,
alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl,
methylsulfonyl or methylsulfonylarnino, where in the case that more than one of
the radicals A1 to A8 have the meaning CR(5), the radicals R(5) are defined
independently of one another.

R(30) and R(31)

independently of one another are hydrogen or alkyl having 1, 2 or 3 carbon
atoms;

or

R(30) and R(31)

together are oxygen or a chain of 2 methylene groups;

or a pharmaceutically tolerable salt thereof, in any stereoisomeric form, or a mixture of any such compounds in any ratio.

2. (Original) The compound as claimed in claim 1, wherein:

A1, A2, A3, A4, A5, A6, A7 and A8

independently of one another are chosen from nitrogen, CH and CR(5), at least one of these groups being nitrogen and at least 4 of these groups being CH;

R(1) is C(O)OR(9), SO₂R(10), COR(11) or C(O)NR(12)R(13)

R(9), R(10), R(11) and R(12)

independently of one another are C_xH_{2x}-R(14);

where x is 0, 1, 2, 3 or 4; and

x cannot be 0 if R(14) is OR(15);

R(14) is alkyl having 1, 2, 3 or 4 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7, 8 or 9 carbon atoms, CF₃, OR(15), substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted biphenyl, substituted or unsubstituted furyl, substituted or unsubstituted thienyl or a substituted or unsubstituted N-containing heteroaromatic having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms,

where substituted phenyl, substituted naphthyl, substituted biphenyl, substituted furyl, substituted thienyl and the substituted N-containing heteroaromatic are each independently substituted by 1, 2 or 3 substituents chosen from F, Cl, Br, I, CF₃, OCF₃, NO₂,

CN, COOMe, CONH₂, COMe, NH₂, OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

R(15) is alkyl having 1, 2, 3, 4 or 5 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, CF_3 , substituted phenyl or unsubstituted phenyl, wherein the substituted phenyl is substituted by 1, 2 or 3 substituents chosen from F, Cl, Br, I, CF_3 , NO_2 , CN, COOMe , CONH_2 , COMe , NH_2 , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R(13) is hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms or CF_3 ;

R(2) is hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms or CF_3 ;

R(3) is $\text{CyH}_{2y}\text{-R}(16)$;
where y is 0, 1, 2, 3 or 4, and
y cannot be 0 if R(16) is OR(17) or SO_2Me ;

R(16) is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7, 8, 9, carbon atoms, CF_3 , OR(17), SO_2Me , substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted furyl, substituted or unsubstituted thienyl or a substituted or unsubstituted N-containing heteroaromatic having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms,
where the substituted phenyl, substituted naphthyl, substituted furyl, substituted thienyl and the substituted N-containing heteroaromatic are each independently substituted by 1, 2 or 3 substituents chosen from F, Cl, Br, I, CF_3 , OCF_3 , NO_2 , CN, COOMe , CONH_2 , COMe , NH_2 , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

R(17) is hydrogen, alkyl having 1, 2, 3, 4 or 5 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, CF_3 , substituted phenyl, unsubstituted phenyl, substituted 2-, 3- or 4- pyridyl, or unsubstituted 2-, 3- or 4- pyridyl
where the substituted phenyl or substituted 2-, 3- or 4- pyridyl are each independently substituted by 1, 2 or 3 substituents chosen from F, Cl, Br, I, CF_3 , OCF_3 , NO_2 , CN, COOMe , CONH_2 , COMe , NH_2 , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

or

R(3) is $\text{CHR}(18)\text{R}(19)$;
where R(18) is hydrogen or $\text{C}_z\text{H}_{2z}\text{-R}(16)$, where R(16) is defined as indicated above;

z is 0, 1, 2 or 3;

R(19) is CONH_2 , $\text{CONR}(20)\text{R}(21)$, $\text{COOR}(22)$ or CH_2OH ;

R(20) is hydrogen, alkyl having 1, 2, 3, 4 or 5 carbon atoms, $\text{C}_v\text{H}_{2v}\text{-}$ CF_3 , substituted $\text{C}_w\text{H}_{2w}\text{-}$ phenyl, or substituted $\text{C}_w\text{H}_{2w}\text{-}$ phenyl,

where the phenyl ring of the substituted $\text{C}_w\text{H}_{2w}\text{-}$ phenyl is substituted by 1, 2 or 3 substituents chosen from F, Cl, Br, I, CF_3 , OCF_3 , NO_2 , CN, COOMe , CONH_2 , COMe , NH_2 , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

v is 0, 1, 2 or 3;

w is 0, 1, 2 or 3;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

R(21) is hydrogen or alkyl having 1, 2, 3, 4 or 5 carbon atoms; and
R(22) is alkyl having 1, 2, 3, 4 or 5 carbon atoms;

R(4) is hydrogen, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms or CF_3 ;

R(5) is independently of one another chosen from F, Cl, Br, I, CF_3 , NO_2 , CN, COOMe , CONH_2 , COMe , NH_2 , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R(30) and R(31) independently of one another are hydrogen or alkyl having 1, 2 or 3 carbon atoms;

or

R(30) and R(31) are a chain of 2 methylene groups;

or a pharmaceutically tolerable salt thereof, in any stereoisomeric form, or a mixture of any such compounds in any ratio.

3. (Currently amended) The compound as claimed in claim 2, wherein A1, A2, A3, A4, A5, A6, A7 and A8 independently of one another are chosen from nitrogen, CH and CR(5), where at least one and at most two of these groups are nitrogen and at least 4 of these groups are CH or a pharmaceutically tolerable salt thereof, in any stereoisomeric form, or a mixture of any such compounds in any ratio. -

4. (Withdrawn) The compound as claimed in claims 1, wherein:

A1, A2, A3, A4, A5, A6, A7 and A8

independently of one another are chosen from nitrogen, CH and CR(5), where at least one and at most two of these groups are nitrogen and at least 4 of these groups are CH;

R(1) is $\text{C}(\text{O})\text{OR}(9)$, $\text{SO}_2\text{R}(10)$, $\text{COR}(11)$ or $\text{C}(\text{O})\text{NR}(12)\text{R}(13)$;

R(9), R(10), R(11) and R(12)

independently of one another are C_xH_{2x} -R(14);

where x is 0, 1, 2, 3 or 4,

x cannot be 0 if R(14) is OR(15);

R(14) is alkyl having 1, 2, 3 or 4 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7, 8 or 9 carbon atoms, CF_3 , OR(15), substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted biphenylyl, substituted or unsubstituted furyl, substituted or unsubstituted thienyl or a substituted or unsubstituted N-containing heteroaromatic having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms;

where the substituted phenyl, substituted naphthyl, substituted biphenylyl, substituted furyl, substituted thienyl and the substituted N-containing heteroaromatic are each independently substituted by 1, 2 or 3 substituents chosen from F, Cl, Br, I, CF_3 , OCF_3 , NO_2 , CN, COOMe, $CONH_2$, COMe, NH_2 , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R(15) is alkyl having 1, 2, 3, 4 or 5 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, CF_3 substituted phenyl or unsubstituted phenyl, wherein the substituted phenyl is substituted by 1, 2 or 3 substituents chosen from F, Cl, Br, I, CF_3 , NO_2 , CN, COOMe, $CONH_2$, COMe, NH_2 , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R(13) is hydrogen

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

R(2) is hydrogen or alkyl having 1, 2 or 3 carbon atoms;

R(3) is $\text{CHR}(18)\text{R}(19)$;

$\text{R}(18)$ is hydrogen or $\text{C}_z\text{H}_{2z}\text{-R}(16)$,

where $\text{R}(16)$ is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7, 8, 9, carbon atoms, CF_3 , $\text{OR}(17)$, SO_2Me , substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted furyl, substituted or unsubstituted thieryl or a substituted or unsubstituted N-containing heteroaromatic having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms,

where the substituted phenyl, substituted naphthyl, substituted furyl, substituted thieryl and the substituted N-containing heteroaromatic are each independently substituted by 1, 2 or 3 substituents chosen from F, Cl, Br, I, CF_3 , OCF_3 , NO_2 , CN, COOMe , CONH_2 , COMe , NH_2 , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

z is 0, 1, 2 or 3;

R(19) is CONH_2 , $\text{CONR}(20)\text{R}(21)$, $\text{COOR}(22)$ or CH_2OH ;

$\text{R}(20)$ is hydrogen, alkyl having 1, 2, 3, 4 or 5 carbon atoms, C_vH_{2v} , CF_3 , substituted C_wH_{2w} -phenyl, or unsubstituted C_wH_{2w} -phenyl

where the phenyl ring of the substituted C_wH_{2w} -phenyl is substituted by 1, 2 or 3 substituents chosen from F, Cl, Br, I, CF_3 , NO_2 , CN, COOMe , CONH_2 , COMe , NH_2 , OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

v is 0, 1, 2 or 3;

w is 0, 1, 2 or 3;

R(21) is hydrogen or alkyl having 1, 2, 3, 4 or 5 carbon atoms;

R(22) is alkyl having 1, 2, 3, 4 or 5 carbon atoms;

R(4) is hydrogen or alkyl having 1 or 2 carbon atoms;

R(5) is independently of one another chosen from F, Cl, Br, I, CF₃, NO₂, CN, COOMe, CONH₂, COMe, NH₂, OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl or methylsulfonyl amino;

R(30) and R(31)

independently of one another are hydrogen or methyl;

5. (Original) The compound as claimed in claim 1, wherein:

A1, A2, A3, A4, A5, A6, A7 and A8

independently of one another are chosen from nitrogen, CH and CR(5), where at least one and at most two of these groups are nitrogen and at least 4 of these groups are CH;

R(1) is C(O)OR(9), SO₂R(10), COR(11) or C(O)NR(12)R(13);

where R(9), R(10), R(11) and R(12)

independently of one another are C_xH_{2x}-R(14);

x is 0, 1, 2, 3 or 4;

R(14) is alkyl having 1, 2, 3 or 4 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7, 8 or 9 carbon atoms, CF₃, substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted biphenyl, substituted or unsubstituted furyl, substituted or unsubstituted thienyl or a substituted or unsubstituted N-containing heteroaromatic having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms,

where the substituted phenyl, substituted naphthyl, substituted biphenyl, substituted furyl, substituted

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

thienyl and the substituted N-containing heteroaromatic are each independently substituted by 1, 2 or 3 substituents chosen from F, Cl, Br, I, CF₃, OCF₃, NO₂, CN, COOMe, CONH₂, COMe, NH₂, OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R(13) is hydrogen;

R(2) is hydrogen or methyl;

R(3) is CyH₂y-R(16);

where y is 0, 1, 2, 3 or 4; and

y cannot be 0 if R(16) is OR(17);

R(16) is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7, 8, 9, carbon atoms, CF₃, OR(17), SO₂Me, substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted furyl, substituted or unsubstituted thienyl or a substituted or unsubstituted N-containing heteroaromatic having 1, 2, 3, 4, 5, 6, 7, 8 or 9 carbon atoms,

where the substituted phenyl, substituted naphthyl, substituted furyl, substituted thienyl and the substituted N-containing heteroaromatic are each independently substituted by 1, 2 or 3 substituents chosen from F, Cl, Br, I, CF₃, NO₂, OCF₃, CN, COOMe, CONH₂, COMe, NH₂, OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R(17) is hydrogen, alkyl having 1, 2, 3, 4 or 5 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, CF₃, substituted phenyl, unsubstituted phenyl, substituted 2-, 3- or 4- pyridyl, or unsubstituted 2-, 3- or 4- pyridyl

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

where the substituted phenyl or substituted 2-, 3- or 4-pyridyl are each independently substituted by 1, 2 or 3 substituents chosen from F, Cl, Br, I, CF₃, NO₂, CN, COOMe, CONH₂, COMe, NH₂, OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl and methylsulfonylamino;

R(4) is hydrogen or alkyl having 1 or 2 carbon atoms;
R(5) is independently of one another chosen from F, Cl, Br, I, CF₃, NO₂, CN, COOMe, CONH₂, COMe, NH₂, OH, alkyl having 1, 2, 3 or 4 carbon atoms, alkoxy having 1, 2, 3 or 4 carbon atoms, dimethylamino, sulfamoyl, methylsulfonyl or methylsulfonylamino;

R(30) and R(31)

independently of one another are hydrogen or methyl; or a pharmaceutically tolerable salt thereof, in any stereoisomeric form, or a mixture of any such compounds in any ratio.

6. (Original) The compound as claimed in claim 5, wherein:

A4 is nitrogen and A1, A2, A3, A5, A6, A7 and A8 independently of one another are chosen from CH and CR(5), where at least 5 of these groups are CH; or a pharmaceutically tolerable salt thereof, in any stereoisomeric form, or a mixture of any such compounds in any ratio.

7. (Original) The compound as claimed in claim 6, wherein:

R(1) is C(O)OR(9), SO₂R(10), COR(11) or C(O)NR(12)R(13); where R(9), R(10), R(11) and R(12) independently of one another are C_xH_{2x}-R(14); where x is 0, 1, 2 or 3;

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

R(14) is alkyl having 1, 2, 3 or 4 carbon atoms, cycloalkyl having 3, 4, 5, 6, 7, 8 or 9 carbon atoms, CF₃, substituted phenyl, unsubstituted phenyl, substituted pyridyl, or unsubstituted pyridyl

where the substituted phenyl and substituted pyridyl are each independently substituted by 1 or 2 substituents chosen from F, Cl, Br, I, CF₃, OCF₃, OH, alkyl having 1, 2 or 3 carbon atoms or alkoxy having 1 or 2 carbon atoms;

R(13) is hydrogen;

R(2) is hydrogen;

R(3) is CyH₂y-R(16);

y is 0, 1 or 2;

R(16) is alkyl having 1, 2, 3 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, CF₃, substituted phenyl, unsubstituted phenyl, substituted pyridyl, or unsubstituted pyridyl

where the substituted phenyl and substituted pyridyl are each independently substituted by 1 or 2 substituents chosen from F, Cl, CF₃, alkyl having 1, 2 or 3 carbon atoms and alkoxy having 1 or 2 carbon atoms;

R(4) is hydrogen;

R(5) is independently of one another chosen from F, Cl, CF₃, CN, COOMe, CONH₂, COMe, NH₂, OH, alkyl having 1, 2 or 3 carbon atoms and alkoxy having 1 or 2 carbon atoms;

R(30) and R(31)

independently of one another are hydrogen or methyl;

or a pharmaceutically tolerable salt thereof, in any stereoisomeric form, or a mixture of any such compounds in any ratio.

8. (Original) The compound as claimed in claim 7, wherein:

R(1) is C(O)OR(9) or COR(11);

R(9) and R(11)

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

independently of one another are $C_xH_{2x}-R(14)$;

where x is 0, 1, 2 or 3;

R(14) is cycloalkyl having 5 or 6 carbon atoms substituted phenyl, or unsubstituted phenyl

where the substituted phenyl is substituted by 1 or 2 substituents chosen from F, Cl, Br, I, CF_3 , OCF_3 , OH, alkyl having 1, 2 or 3 carbon atoms or alkoxy having 1 or 2 carbon atoms;

R(2) is hydrogen;

R(3) is $C_yH_{2y}-R(16)$;

y is 0, 1 or 2;

R(16) is alkyl having 1, 2 or 3 carbon atoms, cycloalkyl having 3, 4, 5 or 6 carbon atoms, substituted phenyl, unsubstituted phenyl, substituted pyridyl, or unsubstituted pyridyl,

where the substituted phenyl and substituted pyridyl are each independently substituted by 1 or 2 substituents chosen from F, Cl, CF_3 , OCF_3 , alkyl having 1, 2 or 3 carbon atoms and alkoxy having 1 or 2 carbon atoms;

R(4) is hydrogen;

R(5) is independently of one another chosen from F, Cl, alkyl having 1, 2, 3 carbon atoms and alkoxy having 1 or 2 carbon atoms;

R(30) and R(31)

are hydrogen;

or a pharmaceutically tolerable salt thereof, in an stereoisomeric form, or a mixture of any such compounds in any ratio.

9. (Original) A pharmaceutical preparation comprising an efficacious amount of at least one of the compounds of claim 1 and at least one additional component chosen from pharmaceutically acceptable vehicles, pharmaceutically acceptable additives and other pharmacological active compounds.

10. (Original) A method for treating or preventing a K⁺ channel-mediated diseases comprising administering to a patient an effective amount of at least one compound chosen from the compounds as claimed in claim 1.
11. (Original) A method for treating or preventing cardiac arrhythmias which can be eliminated by action potential prolongation comprising administering to a patient an effective amount of at least one compound chosen from the compounds as claimed in claim 1.
12. (Original) A method for treating or preventing reentry arrhythmias comprising administering to a patient an effective amount of at least one compound chosen from the compounds as claimed in claim 1.
13. (Original) A method for treating or preventing supraventricular arrhythmias comprising administering to a patient an effective amount of at least one compound chosen from the compounds as claimed in claim 1.
14. (Original) A method for treating or preventing atrial fibrillation or atrial flutters comprising administering to a patient an effective amount of at least one compound chosen from the compounds as claimed in claim 1.
15. (Original) A method for terminating atrial fibrillation or atrial flutters comprising administering to a patient an effective amount of at least one compound chosen from the compounds as claimed in claim 1.
16. (Original) A pharmaceutical preparation, comprising an efficacious amount of at least one compound chosen from the compounds as claimed in claim 1, at least one IKr channel blocker, and at least one additional ingredient chosen from pharmaceutically acceptable vehicles and pharmaceutically acceptable additives.

17. (Original) A pharmaceutical preparation, comprising an efficacious amount of at least one compound chosen from the compounds as claimed in claim 1, at least one IKs channel blocker, and at least one additional ingredient chosen from pharmaceutically acceptable vehicles and pharmaceutically acceptable additives.
18. (Original) A pharmaceutical preparation, comprising an efficacious amount of at least one compound chosen from the compounds as claimed in claim 1, at least one beta blocker, and at least one additional ingredient chosen from pharmaceutically acceptable vehicles and pharmaceutically acceptable additives.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com